Incyte price target raised to $75 from $44 at Jefferies Jefferies raised its price target for Incyte shares to $75 from $44 on expectations the company's IDO inhibitor with ipilimumab for melanoma could "unlock huge value." The firm says it heard positive commentary from four investigators involved in the Phase 2 study and keeps a Buy rating on the stock.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Novartis announces Phase III study for Jakavi meets primary endpoint Novartis announced that a pivotal Phase III trial of Jakavi, ruxolitinib, compared to best available therapy has met its primary endpoint of maintaining hematocrit control without the need for phlebotomy, a procedure to remove blood from the body to reduce the concentration of red blood cells, and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea. The safety profile of Jakavi was generally consistent with previous studies based on initial review of the data. Data from the study will be presented at an upcoming medical congress and submitted to worldwide regulatory authorities this year.